Emailed Statement from BMS/Amylin

Mr. Carroll:

Bristol-Myers Squibb expects to maintain a presence in San Diego into 2014. As we continue to align the work of Amylin's commercial, R&D, manufacturing, corporate staff and administrative functions with their respective functions at Bristol-Myers Squibb, we are eliminating redundant positions in order to simplify our operations, reduce costs and increase our efficiency. This is consistent with our stated intention to rapidly integrate Amylin into Bristol-Myers Squibb and to enhance and accelerate the value of Amylin's robust GLP-1 diabetes portfolio and its innovative R&D programs through our global alliance with AstraZeneca, while also simplifying operations. 

By the end of 2014, we plan to have all work being done in San Diego transitioned to other Bristol-Myers Squibb sites. Beyond that, we will likely have a small number of people working on closing the San Diego facilities by the end of Q1 2015. As you note below, Amylin employs about 420 people in San Diego. Most work in commercial, R&D, manufacturing, corporate staff and administrative roles. Where appropriate, Amylin employees in San Diego will be considered for relocation if they are interested.

As you also noted below, Amylin has 300-plus employees at a manufacturing plant in West Chester, Ohio, and nearly 400 in field-based sales and medical roles. These positions are being integrated into Bristol-Myers Squibb. The changes in staffing levels (1,250 at acquisition versus 1,100 today) are due to both voluntary and involuntary departures. In January 2013, 67 positions located at or reporting into Amylin's San Diego headquarters were eliminated. In February, an additional 36 positions located at or reporting into Amylin's San Diego headquarters were eliminated. In both cases, most of the affected employees worked in commercial, corporate staff or administrative roles. There will continue to be staffing reductions throughout the integration process. San Diego employees who are not offered the opportunity to relocate will be offered severance packages and career transition services. An estimated 100-125 employees at Amylin's San Diego headquarters will be offered the opportunity to relocate to other Bristol-Myers Squibb facilities. We are unable to predict how many San Diego-based employees will accept relocation offers.  

Thank you for your interest in Bristol-Myers Squibb and Amylin Pharmaceuticals.

FREDERICK J. EGENOLF | Director, Corporate Communications & Community Affairs
Bristol-Myers Squibb
P.O. Box 4000, Princeton, N.J. 08543-4000
Phone: 609.252.4875

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.